Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 6/20 | 0.62 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.59 |
| ▸ | CTSL | P07711 | 3/20 | 0.55 |
| ▸ | CTSS | P25774 | 3/20 | 0.55 |
| ▸ | CTSK | P43235 | 3/20 | 0.55 |
| ▸ | CTSH | P09668 | 1/20 | 0.55 |
| ▸ | DPP3 | Q9NY33 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.55 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.54 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.54 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.54 |
| ▸ | TACR1 | P25103 | 1/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.54 |
| ▸ | TACR2 | P21452 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6041194 | 0.95 | CXCR4 (0.61) | KISS1RCXCR4CTSLCTSSCTSK | |
| SCHEMBL6041189 | 0.95 | CXCR4 (0.61) | KISS1RCXCR4CTSLCTSSCTSK | |
| SCHEMBL30288110 | 0.93 | KISS1R (0.61) | KISS1RCXCR4DPP3NTSR2NTSR1 | |
| SCHEMBL29978571 | 0.93 | CXCR4 (0.59) | KISS1RCXCR4CTSLCTSSCTSK | |
| SCHEMBL31273381 | 0.93 | KISS1R (0.61) | KISS1RCXCR4CTSLCTSSCTSK | |
| SCHEMBL30608431 | 0.92 | KISS1R (0.61) | KISS1RCXCR4CTSLCTSSCTSK | |
| SCHEMBL31005883 | 0.92 | KISS1R (0.57) | KISS1RCXCR4CTSLCTSSCTSK | |
| SCHEMBL31194149 | 0.92 | KISS1R (0.62) | KISS1RCXCR4CTSLCTSSCTSK | |
| SCHEMBL31238548 | 0.91 | KISS1R (0.62) | KISS1RCXCR4CTSLCTSSCTSK | |
| SCHEMBL29350708 | 0.91 | DPP3 (0.64) | KISS1RCXCR4DPP3NTSR2NTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220152205-A1 | MODULATING PERMEABILITY OF THE BLOOD CEREBROSPINAL FLUID BARRIER | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-05-19 | — | — | US | claimed |
| EP-3377104-B1 | MODULATING PERMEABILITY OF THE BLOOD CEREBROSPINAL FLUID BARRIER | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-12-21 | — | — | EP | disclosed |
| US-20220152205-A1 | MODULATING PERMEABILITY OF THE BLOOD CEREBROSPINAL FLUID BARRIER | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-05-19 | — | — | US | disclosed |
| US-11305014-B2 | Modulating permeability of the blood cerebrospinal fluid barrier | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11305014-B2 | Modulating permeability of the blood cerebrospinal fluid barrier | C3AR1, CFH, CSF3R | KISS1R 1201/4885CXCR4 164/4885CTSL 472/4885 |
| US-20220152205-A1 | MODULATING PERMEABILITY OF THE BLOOD CEREBROSPINAL FLUID BARRIER | C3AR1, CFH, CSF3R | KISS1R 1201/4885CXCR4 164/4885CTSL 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.